THE LEVELS OF IL-4 AND IL-8 IN SERUM OF PATIENTS WITH CHRONIC GASTRITIS AND ULCERATIVE DISEASE OF STOMACH AND DUODENUM

Abstract

Local inflammation in H. pylori infection is characterized by infiltration of the gastric mucosa by neutrophils and specific lymphocytes, an increase in the production of immunoregulatory, pro- and anti-inflammatory cytokines. IL-4 is the most important regulatory cytokine that plays a role in a huge number of immune and non-immune functions. IL-8 is a potent angiogenic factor and chemoattractant, its presence in the circulation can have a systemic pro-inflammatory effect on the body. IL-4 and IL-8 in H. pylori infection has been studied insufficiently. The goal is to establish serum levels of IL-4 and IL-8 in patients with chronic gastritis and peptic ulcer and duodenal ulcer. Materials and methods. 95 patients of the gastroenterological department were examined, of them 37 men and 58 women (mean age 59 years): 53 patients diagnosed with chronic active gastritis (CAG, including erosive gastroduodenitis) and 42 patients diagnosed with peptic ulcer (PU). Patients were conditionally divided into 4 subgroups: PU (without confirming the presence in patients with Hp according to generally accepted methods), PU + Hp (patients with the presence of Hp), CAG and CAG + Hp. Results. An increase in serum IL-4 levels (above 10 pg / ml) was observed in only 50.7% of patients, with approximately the same frequency in patients with CAG and PU, and an increase in serum IL-8 levels (above 0.062 ng / ml) - in most patients (90%), and the highest levels of IL8 were detected in patients with PU + Hp. In the first analysis, 31% of patients had elevated levels of IL-8 in the absence of IL-4, while in the second analysis - already 62% of patients (p ≤ 0.01). This indicated a sharp twofold decrease in the production of IL-4 in just a few days between the two analyzes. Conclusion. Considering that an increase in serum levels of IL-8 is found in a larger number of patients than IL-4, which, moreover, ceases to be detected in serum, it can be assumed that the production and anti-inflammatory effect of IL-4 are insufficient in some patients with gastritis and peptic ulcer disease. Against this background, elevated levels of IL-8 can help maintain inflammation in a significant number of patients, as well as reduce the effectiveness of eradication therapy.

Keywords

H. pylori infection / chronic gastritis / peptic ulcer disease / interleukin 4 / interleukin 8

References

[1] S. Zhang, Joseph Desrosiers, Jose R. Aponte-Pieras, Kristen DaSilva, Loren D. Fast, Frances Terry, et al. Human Immune Responses to H. pylori HLA Class II Epitopes Identified by Immunoinformatic Methods. PLOS ONE. 2014; 9 (4): e94974.

[2] McColl KE (2010) Clinical practice. Helicobacter pylori infection. N Engl J Med. 362: 1597-1604. PMID: 20427808.

[3] Vinagre R.M.D.F., Vinagre I.D.F., Vilar-e-Silva A., Fecury A.A. and Martins L.C. Helicobacter pylori infection and immune profile of patients with different gastroduodenal diseases. Arq Gastroenterol. 2018; 55 (2): 122-7. dx.doi.org/10.1590/S0004-2803.201800000-21.

[4] Nomura M, Lee J, Temmermann GN, Nomura RY, Perez-Perez GI, Blaser MJ.Helicobacter pylori CagA seropositivity and gastric carcinoma risk in a Japanese American population. J Infect Dis. 2002; 186: 1138-44.

[5] Higashi H, Nakaya A, Tsutsumi R, Yokoyama K, Fujii Y, Ishikawa S, et al. Helicobacter pylori CagA induces Ras-independent morphogenetic response through SHP-2 recruitment and activation. J Biol Chem. 2004; 23:17205-16.

[6] Serrano C, Diaz MI, Valdivia A, Godoy A, Pena A, Rollan A, et al. Relationship between Helicobacter pylori virulence factors and regulatory cytokines as predictors of clinical outcome. Microbes Infect. 2007; 9:428-3.

[7] Sommer F, Faller G, Konturek P, Kirchner T, Hahn EG, Zeus J, et al. Antrum and corpus mucosa-infiltrating CD4+ lymphocytes in Helicobacter pylori gastritis display a Th1 phenotype. Infect Immun. 1998; 6: 5543-46).

[8] Симбирцев А.С. Цитокины в патогенезе и лечении заболеваний человека. Сиб: Фолиант. 2018.

[9] Ярилин А.А. Иммунология: учебник. М.; ГЭОТАР-Медиа, 2010.

[10] Ohara J, Paul WE. Receptors for B-cell stimulatory factor-1 expressed on cells of haematopoietic lineage. Nature. 1987a; 325:537-540. [PubMed: 3100961]

[11] Howard M, Farrar J, Hilfiker M, Johnson B, Takatsu K, Hamaoka T, Paul WE. Identification of a T cell-derived B cell growth factor distinct from interleukin 2. J Exp Med. 1982; 155:914-923. [PubMed: 6977612]

[12] Sideras P, Bergstedt-Lindqvist S, Severinson E. Partial biochemical characterization of IgG1-inducing factor. Eur J Immunol. 1985; 15: 593-8. [PubMed: 3874072]

[13] Coffman RL, Ohara J, Bond MW, Carty J, Zlotnik A, Paul WE. B cell stimulatory factor-1 enhances the IgE response of lipopolysaccharide-activated B cells. J Immunol. 1986; 136: 4538-41. [PubMed: 3486902].

[14] Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013; 368: 2455-66. [PubMed: 23688323].

[15] William E. Paul History of Interleukin-4 Cytokine. 2015 September ; 75(1): 3-7. doi:10.1016/j.cyto.2015.01.038.

[16] Akash H. Verma, Chelsea L. Bueter, Marc E. Rothenberg, and George S. Deepe Jr. Eosinophils Subvert Host Resistance to an Intracellular Pathogen by Instigating Non-Protective IL-4 in CCR2-/- Mice. Mucosal Immunol. 2017 January; 10(1): 194-204. doi:10.1038/mi.2016.26.

[17] Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med. 2002; 347:1175-86.

[18] Israel DA, Peek RM. Review article: pathogenesis of Helicobacter pylori-induced gastric inflammation. Aliment Pharmacol Ther. 2001; 15:1271-90.

[19] Crabtree, 1996; Crabtree, J.E. (1996). Gastric mucosal inflammatory responses to Helicobacter pylori. Aliment Pharmacol. Ther. Suppl. 10, 29-37. PMID: 8730257. doi: 10.1046/j.1365-2036.1996.22164003.x

[20] Naumann and Crabtree, 2004 Naumann, M., and Crabtree, J. E. (2004). Helicobacter pylori-induced epithelial cell signalling in gastric carcinogenesis. Trends Microbiol. 2004. 12, 29-36. PMID: 14700549. doi: 10.1016/j.tim. 2003.11.005).

[21] Tafreshi M., Guan J., Gorrell R.J., Chew N., Xin Y., Deswaerte V., et al. Helicobacter pylori Type IV Secretion System and Its Adhesin Subunit, Cag L, Mediate Potent Inflammatory Responses in Primary Human Endothelial Cells. Front. Cell. Infect. Microbiol. 2018. 8:22. PMID: 29468142. doi: 10.3389/fcimb.2018.00022.

[22] Kusters et al., 2006 Kusters, J. G., van Vliet, A. H., and Kuipers, E. J. (2006). Pathogenesis of Helicobacter pylori infection. Clin. Microbiol. Rev. 19, 449-490. PMID: 16847081. doi: 10.1128/CMR.00054-05.

[23] Кононов А.В. Воспаление как основа Helicobacter pylori-ассоциированных болезней. Архив патологии. 2006; 68 (5): 3-10.

[24] Bayraktaroglu T, Aras AS, Aydemir S, et al. Serum levels of tumor necrosis factor-a, interleukin-6 and interleukin-8 are not increased in dyspeptic patients with Helicobacter pylori-associated gastritis. Mediators Inflamm. 2004; 13: 25-8. PMID: 15203561. DOI: 10.1080/09629350410001664789.

[25] Siregar G.A., Halim S., Sitepu R.R. Serum TNF-α, IL-8, VEGF Levels in Helicobacter pylori Infection and Their Association with Degree of Gastritis. Acta Medica Indonesiana, 2015; 47(2): 120-6.

[26] Nagashima H., Iwatani S., Cruz M., Abreu J.A.J., Tronilo L., Rodríguez E. et al. Differences in interleukin-8 expression in Helicobacter pylori-infected gastric mucosa tissues from patients in Bhutan and the Dominican Republic Hum Pathol. 2015 January; 46(1): 129-36. PMID: 25454482. doi:10.1016/j.humpath.2014.10.006.

[27] Циммерман Я.С. Язвенная болезнь: критический анализ современного состояния проблемы. Экспериментальная и клиническая гастроэнтерология. 2018; 149(1): 80-9.

[28] Национальные рекомендации по диагностике и лечению кислотозависимых и ассоциированных с Helicobacter pylori заболеваний (VI Московское соглашение) от 24-25 ноября 2016 г. http://www.nogr.org/images/Article/2017/G_02_2017_in_-1_003-021.pdf

RIGHTS & PERMISSIONS

Eco-vector